fda tirzepatide shortage update says of GLP-1 is over Breaking News: OFA Challenges FDA

In the SURMOUNT trials for obesity, gastrointestinal adverse events increased with dose: 39% at 5 mg, 46% at 10 mg, and 49% at the 15 mg dose

Hypoglycemia: Monitor blood glucose levels closely, especially if using insulin

If tirzepatide doesnt work for you, other approaches exist

They are common and harmless in the syringe, but they take up space that should be occupied by medication, which means you could end up with a slightly lower dose than intended

The math is actually simple once someone explains it clearly

potential side effects in the breastfed child due to this drug or the mother's underlying condition should be considered